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Summary
Pulmonary valve endocarditis is a rare type of infective endocarditis (IE). Streptococcus 
pneumoniae is a pathogen that is uncommonly associated with IE. A 50 year-old male 
was referred to us after an incidental echocardiographic finding of a pulmonary valve 
vegetation. The patient had a recent admission for drainage of a scrotal abscess from 
which S. pneumoniae was isolated, complicated by hospital acquired pneumonia and 
pulmonary embolism. Analysis using polymerase chain reaction of the surgically resected 
mass revealed signs of 16S ribosomal DNA consistent with S. pneumoniae infection. This 
was an extremely rare case of pneumococcal pulmonary valve IE presenting entirely 
asymptomatically in the absence of any known risk factors.
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Learning points:
 • Streptococcus pneumoniae endocarditis can present with very few symptoms or even entirely asymptomatically, as 
in this case.
 • Pulmonary valve endocarditis can affect healthy patients, even in the absence of any known predisposing risk 
factors or pre-existing heart conditions.
 • An echocardiogram may be considered following severe infection with sepsis by pneumococci, to screen for 
vegetations that could evolve silently over the following weeks.
Background
This report describes a case of pulmonary valve 
endocarditis due to Streptococcus pneumoniae, presenting 
entirely asymptomatically in a healthy individual. This 
case carries significant educational messages and promotes 
clinical knowledge and diagnostic reasoning by:
 • Presenting a case that is unique.
 • Clearly presenting our dilemmas and clinical questions 
in this rare case of infective endocarditis, for the 
management of which there is no clear guidance.
 • Relating echocardiographic images with high-quality 
intra-operative images of the vegetation and the 
perforated pulmonary valve cusp causing significant 
regurgitation.
Case presentation
A 50  year-old male was referred to the Cardiology 
Department as a suspected case of endocarditis after the 
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incidental finding of an echogenic mass on the pulmonary 
valve seen in an outpatient echocardiogram (Fig. 1). This 
patient had presented three months prior to this admission 
with pain and swelling in the left testicle for 4  days, 
which was confirmed to be an epididymo-orchitis on an 
ultrasound scan and was treated with oral ciprofloxacin for 
10  days, anti-inflammatories and scrotal support. About 
two weeks later, the patient re-presented with fever and 
rigors, persistent testicular pain and swelling. Exploration 
revealed a left hemiscrotal abscess, which was drained 
and S. pneumoniae was isolated from the pus. Moreover, a 
urine antigen test was positive for S. pneumoniae antigen. 
The patient was treated as an inpatient with clindamycin 
IV for 8 days and ciprofloxacin orally for another 6 days. 
Repeated blood cultures came back as negative. This 
admission was further complicated by a left lower lobe 
pneumonia and bilateral pulmonary emboli (Fig. 2), which 
was treated with levofloxacin, tazocin and meropenem IV. 
The patient was also started on rivaroxaban 20 mg daily in 
consultation with the respiratory team.
Investigation
An echocardiogram revealed mild pericardial effusion, 
with a maximum depth of 18 mm around the left 
ventricular posterior wall (Fig. 2). A repeat echocardiogram 
about one week later showed some improvement in the 
pericardial effusion, with a greatest maximum depth of 
14 mm. Both scans did not show any vegetations. The 
patient recovered fully and was discharged home with 
an outpatient follow-up echocardiogram. Six weeks later, 
the follow-up echocardiogram revealed a suspicious 
echogenic mass, which was very mobile and appeared 
to be attached to the pulmonary valve causing turbulent 
flow and flow acceleration (Fig.  1). It was 21.4 × 18 mm 
in largest dimensions. This finding warranted admission 
for suspected pulmonary valve endocarditis (PVE). There 
was no history of congenital heart disease, valvulopathy 
or previous infective endocarditis, and no risk factors of 
immunosuppression. On examination, the patient was 
completely asymptomatic, with no fever, night sweats 
or any other constitutional symptoms. There were no 
stigmata of infective endocarditis. All observations were 
normal, and there was no evidence of sepsis. The patient’s 
latest blood tests showed a hemoglobin of 119 g/L, white 
cell count of 6.3 × 109/L, neutrophils of 3.50 × 109/L 
and a CRP of 21 mg/L. Urea, electrolytes and the liver 
function tests were within normal limits. Repeated blood 
cultures came back as negative. Additional tests for the 
HACEK micro-organisms as well as serology for Q-fever, 
Bartonella and Whipple’s disease were requested, which 
all came back as negative. The patient also tested negative 
for HIV infection. A repeat CT pulmonary angiogram 
did not reveal any new pulmonary emboli and showed 
partial resolution of the previously identified ones. In 
view of the typical appearance of the vegetation on the 
echocardiogram, as well as the presence of pulmonary 
arterial emboli, we decided that it was very likely that 
this was a case of infective endocarditis causing septic 
emboli. Therefore, the patient was started on amoxicillin 
and gentamicin IV as per local microbiology protocol. The 
patient was then transferred to a tertiary cardiothoracic 
center where the patient underwent a transoesophageal 
echocardiogram (TOE) and then surgical resection of the 
mass. The TOE showed a severely deformed pulmonary 
valve with a large vegetation attached on the valve and 
severe pulmonary regurgitation (Fig. 3). Intraoperatively, 
the pulmonary valve was destroyed with a large vegetation 
attached to it and a perforated left pulmonary valve cusp 
causing severe regurgitation was also revealed (Fig. 4).
Treatment and outcome
A 25 mm stentless bioprosthesis was implanted in the 
pulmonary position. The procedure was uneventful and 
a post-operative TOE did not show any regurgitation. 
Valve cultures came back as negative but polymerase 
chain reaction showed signs of 16S ribosomal DNA (rDNA) 
consistent with S. pneumoniae infection. The patient made a 
good recovery and was discharged home on IV antibiotics: 
cefuroxime 2 g IV for 2 weeks post discharge.
Figure 1
An echogenic mass on the pulmonary valve seen in the outpatient 
echocardiogram.





This is a rare case of PVE with a very uncommon clinical 
course and causative organism. There are many puzzling 
features that challenged our diagnostic reasoning, such as:
 • What was the entry point of the organism? Potential 
entry sites could have been: the testicular abscess, the 
venous access used for IV antibiotics or a pneumonia 
causing chest sepsis.
 • Whether pneumonia was primary or secondary to 
septic emboli.
 • Whether there were any concomitant thrombotic 
emboli; the repeat CT pulmonary angiogram did 
not identify any further emboli, but the patient had 
already been started on rivaroxaban following the first 
episode of bilateral pulmonary embolism; however, 
the fact that there were still residual vascular occlusive 
images six weeks later might suggest vegetation 
material.
 • Why the vegetation appears to have grown, while 
the patient was apyretic, having been treated with 
microbiology guided antibiotics?
 • Whether the potential embolic risk of such large 
vegetation was important enough to warrant surgical 
intervention in the absence of signs of infection.
 • Could we be certain of having achieved full sterilization 
of the vegetation? Should we restart antibiotics in an 
asymptomatic male with no evidence of infection?
In the first two admissions due to epididymo-orchitis, 
there was nothing to suggest the presence of infective 
endocarditis clinically, as well as in the two inpatient 
echocardiograms (done after the development of 
pulmonary emboli), which only showed some pericardial 
effusion. Cultures from the testicular abscess as well as a 
urine antigen test, revealed infection with S. pneumoniae, 
which is a rare causative organism of epididymo-orchitis 
(1). The patient’s course was complicated by chest sepsis, 
but no causative organism was identified in his blood and 
sputum cultures. Infective endocarditis was suspected 
following the incidental finding of a large vegetation on 
an outpatient echocardiogram six weeks later, which had 
been arranged in order to monitor for the resolution of 
the pericardial effusion and also based on the history of 
bilateral pulmonary emboli. Clinically, the patient was 
completely asymptomatic. According to the modified 
Duke’s criteria, at this point in time, the patient fulfilled 
1 major (positive echocardiogram) and one minor (septic 
pulmonary infarcts) criteria. This classified as a possible 
case of infective endocarditis. We felt that the multiple 
and prolonged courses of IV and oral antibiotics received 
for the epididymo-orchitis and chest sepsis could have 
contributed to partial sterilization of the vegetation, the 
lack of systemic symptoms and the repeated negative 
blood cultures. We decided to commence treatment for 
infective endocarditis pending further discussion with the 
cardiothoracic surgeons with a view to obtaining a biopsy 
of the mass in order to establish a definite diagnosis. In 
Figure 2
Pulmonary embolism on CTPA (left). Pericardial 
effusion around the left ventricular posterior wall 
(right).
Figure 3
TOE echo showing disruption of the architecture of the 
pulmonary valve and a swinging vegetation attached to it 
(left). Pulmonary valve regurgitation was also 
demonstrated (right).
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view of the size of the vegetation, the embolic risk had to 
be considered. The ESC guidelines for the management 
of infective endocarditis do not clearly state the role of 
surgery when the pulmonary valve is infected (2). After 
discussion with our cardiothoracic surgical colleagues, 
it was decided to proceed with urgent inpatient surgical 
resection of the mass. The results from the histological 
analysis of the sample confirmed the presence of infective 
endocarditis. Interestingly, the PCR analysis of the valve 
tissue revealed S. pneumoniae 16S rDNA, which was the 
same causative organism as the one identified in the 
scrotal pus and the one that was suggested from the 
positive urine antigen test. With that evidence, the patient 
now fulfilled the Duke’s criteria of infective endocarditis.
The entry point of the offending organism was another 
puzzling feature in this case. Although the scrotal abscess 
could potentially be the entry point of the infection, 
there has never been a report of streptococcal endocarditis 
secondary to testicular infection. Primary pneumococcal 
orchitis is also extremely rare. In fact, during the course 
of pneumococcal septicemia due to endocarditis, 
bacteria may reach many sites where they can multiply 
and produce purulent lesions. Pneumococcal arthritis, 
vertebral osteomyelitis, ophthalmitis and orchitis may 
be produced this way (1). However, in our case, there was 
no evidence of endocarditis at the time of the first illness 
due to epididymo-orchitis (the patient had 2 inpatient 
echocardiograms, which did not reveal any obvious 
vegetations). Right-sided infective endocarditis presenting 
with systemic illness and testicular swelling, orchitis and 
pulmonary emboli due to Staphylococcus aureus tricuspid 
endocarditis has been reported once (3), but there are 
no reports of a similar presentation of a pneumococcal 
PVE. Our study is the only one linking orchitis with 
pneumococcal PVE. S. pneumoniae is a very rare causative 
organism of infective endocarditis (4), and in the majority of 
the cases, there is some underlying condition predisposing 
to infective endocarditis; this was unlikely in our case, as 
the patient had no known risk factors. Secondly, PVE is 
also very rare and typically occurs in 1.5–2% of patients 
hospitalized with IE (5). It is usually associated with 
simultaneous involvement of other valves (6), commonly 
in the context of an underlying structural heart disease. 
A total of 70 cases of isolated PVE have been reported 
between 1979 and 2013 (6). Clinical manifestations of 
PVE commonly affect the respiratory system owing to 
pulmonary septic embolization. Intravenous drug abuse, 
alcoholism, sepsis, immunosuppression and catheter-
related infections or other unique aetiologies account for 
the majority of predisposing factors, as well as infection 
with Neisseria gonorrhea which appears to have a particular 
affinity for the pulmonary valve (7, 8, 9, 10). Pulmonary 
valve endocarditis in structurally normal hearts, as in this 
patient, is an extremely rare entity.
Right-sided IE usually involves the tricuspid valve 
rather than the pulmonary valve (11). This is possibly 
due to the lower pressure gradient across the pulmonary 
valve that leads to less shear stress (7), therefore causing 
less valvular damage. The clinical course of PVE tends 
to be less typical than that of left-sided IE and the final 
diagnosis of PVE may be delayed. Typical signs of IE 
may be absent as in this case, but in the majority of the 
cases, the patients present with symptoms and sings of 
sepsis. Four to six weeks of intravenous antibiotics are 
the primary mode of treatment. Abscess formation, valve 
obstruction or severe regurgitation, large vegetations at 
risk of emboli formation and persistence of the infection 
despite antibiotic treatment would warrant surgery 
(12). Surgery for PVE is recommended in patients with 
persisting vegetations >10 mm after one or more clinical 
or silent embolic events despite appropriate antibiotic 
treatment, although it is generally not advisable in 
the IVDU population (12). Surgery undertaken for the 
prevention of embolism must be performed very early, 
during the first few days following initiation of antibiotic 
therapy, as the risk of embolism is highest at this time 
(13). As with all right-sided IE, PVE has a better prognosis 
than left-sided IE and most of the cases respond well to 
appropriate antibiotic therapy (14).
In conclusion, this is the first confirmed case 
of pneumococcal pulmonary valve endocarditis, 
following pneumococcal orchitis, presenting entirely 
Figure 4
Intraoperative photograph of gross surgical findings demonstrating the 
large vegetation (arrow) attached to the pulmonary valve (left). 
Intraoperative photograph showing a perforated left pulmonary valve 
cusp (right).




asymptomatically in the absence of any known 
predisposing risk factors. An extensive literature review 
could not identify any similar case. It suggests that an 
echocardiogram may be recommended following severe 
infection with sepsis by pneumococci, to screen for 
vegetations that could evolve silently over the following 
weeks.
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